# Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

> **NCT07276880** · PHASE2 · RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 32 (estimated)

## Conditions studied

- Breast Cancer
- Triple Negative Breast Cancer (TNBC)
- HER2-Negative Breast Carcinoma
- Node-positive Breast Cancer

## Interventions

- **DRUG:** Neoadjuvant Pembrolizumab
- **RADIATION:** low dose neoadjuvant boost
- **RADIATION:** High dose neoadjuvant boost

## Key facts

- **NCT ID:** NCT07276880
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2027-11
- **Final completion:** 2032-01
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-04-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07276880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07276880, "Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07276880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*